Aptose Biosciences, Inc. (APTO) Trading Down 11.7%
Aptose Biosciences, Inc. (NASDAQ:APTO) (TSE:APS) was down 11.7% during trading on Tuesday . The company traded as low as $1.43 and last traded at $1.44. Approximately 1,467,285 shares were traded during trading, an increase of 281% from the average daily volume of 385,331 shares. The stock had previously closed at $1.63.
A number of equities research analysts recently commented on APTO shares. Zacks Investment Research upgraded Aptose Biosciences from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a research report on Monday, August 14th. HC Wainwright upgraded Aptose Biosciences from a “neutral” rating to a “buy” rating and increased their price target for the stock from $1.00 to $4.00 in a research report on Thursday, September 7th. ValuEngine lowered Aptose Biosciences from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Finally, Rodman & Renshaw started coverage on Aptose Biosciences in a research report on Thursday, June 8th. They set a “neutral” rating on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $6.50.
The company has a 50 day moving average price of $1.48 and a 200-day moving average price of $1.23. The firm’s market cap is $36.04 million.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.07. Equities research analysts anticipate that Aptose Biosciences, Inc. will post ($1.09) earnings per share for the current year.
About Aptose Biosciences
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.